Lipoprotein (a) as an acute phase reactant in patients on chronic hemodialysis

Bosnian Journal of Basic Medical Sciences

Volumn 10, Issue 1, 2010, Pages 19-25

  Topçu Shufta, Valdete ^a   Begolli, Luljeta ^a   Kryeziu, Emrush ^a  

^a UNIVERSITY OF PRISHTINA   (Serbia)

Author keywords

Acute phase reactant; CRP; HDL C; Lp(a); Serum albumin

Indexed keywords

EID: 77949414010     PISSN: 15128601     EISSN: None     Source Type: Journal    
DOI: 10.17305/bjbms.2010.2728     Document Type: Article

References (35)

1. Longenecker J.C., Coresh J., Powe N.R. et al. Traditional Cardiovascular Disease Risk Factors in Dialysis Patients Compared with the General Population: The CHOICE Study. J. Am. Soc. Nephrol. 2002; 13:1918-1927.
2. Hoover-Plow J. Elusive proatherothrombotic role of Lp(a): a new direction? J. Thromb. Haemost. 2006; 4(5): 971-972
3. Hajjar K.A., Gavish D., Breslow J.L., Nachman R.L. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989; 339(6222)303-305.
4. Argraves K.M., Kozarsky K.F., Fallon J.T.,Harpel P.C., Strickland D.K. The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J. Clin. Invest. 1997 ; 100(9): 2170-2181.
5. Dahlén G.H., Stenlund H. Lp(a) lipoprotein is a major risk factor for cardiovascular disease: pathogenic mechanisms and clinical significance. Clin. Genet. 1997;52(5):272-280.
6. Holmes D.T., Schick B.A., Humphries K.H., Frohlich J. Lipoprotein(a) Is an Independent Risk Factor for Cardiovascular Disease in Heterozygous Familiar Hypercholesterolemia. Clin. Chem. 2005;51: 2067-2073.
7. Quashing T., Krane V., Metzger T.,Warner C. Abnormalities in Uremia lipoprotein metabolism and its impact on Cardiovascular disease. Am. J. Kid. Dis. 2001; 38(4): 514-519.
8. Longenecker J.C., Klag M.J., Marcovina S.M. et al. High Lipoprotein(a) Levels and Small Apolipoprotein(a) Size Prospec-tively Predict Cardiovascular Events in Dialysis Patients. Am. Soc. Nephrol. 2005;16: 1794-1802.
9. Greiber S., Wanner C. Lipoprotein (a) in nephrotic syndrome and end stage disease. Miner. Electrol. Metab.1997; 23: 161-165.
10. Dieplinger H., Lacner C., Kronenberg F. et al. Elevated plasma concentrations of lipoprotein (a) in patients with end stage renal disease are not related to the size polymorphism of apolipoprotein (a). J. Clin. Ivest. 1993; 91: 397-401.
11. Riella M. Malnutrition in Dialysis: Malnourishment or uremic inflammatory response. Kidney Int. 2000; 57: 1211-1233.
12. 2 Cells in Haemodialysis Patients. Nephron 1999; 83: 237-245.
13. Cohen G., Haag-Weber M., Horl W.H. Immune dysfunction in uremia. Kidney Int. Suppl. 1997; 62: S79-S82.
14. Sester U., Sester M., Heine G. Strong depletion of CD14+ CD16+ monocytes during haemodialysis treatment. Nephrol. Dial. Transplant 2001; 16: 1402-1408.
15. Panichi V., Migliori M., De Pietro S. et al. The link of biocompat-ibility to cytokine production. Kidney Int. 2000;76: S96-S103.
16. Perez-Garcia R., Rodriguez-Benitez P. Why and how to monitor bacterial contamination of dialysate? Nephrol. Dial. Transplant. 2000; 15: 760-764.
17. Zaoui, P., Hakim, R.M. The effects of the dialysis membrane on cytokine release. J. Am. Soc. Nephrol. 1994; 4: 1711-1718.
18. Blaton V. Dyslipidemia at chronic renal failure. New trends in classification, diagnosis and management of kidney diseases. The 8th EFCC Continuous Postgraduate Course in Clinical Chemistry. Dubrovnik, Croatia, 2008; pp:54-60.
19. Kleemann R., Zadelaar S., Kloostra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc. Res. 2008; 79: 340-376.
20. Ridker P., Hennekens Ch., Buring J., Rifal N. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med.2000; 343 (12): 836-843.
21. Van Lenten B., Reddy S., Navah M., Fogelman A. Understanding changes in high density lipoproteins during the acute phase response. Arterioscler. Tromb. Vasc. Biology 2006; 26: 1687-1688.
22. Richard J.L., Warnet J.M., Ducimetiere P. Decreased levels of the albumin-alpha-l-globulin fraction of serum proteins, risk factor for ischemic cardiopathy. Rev. Epidemiol. Sante Publique 1985; 33:347-351.
23. Foley R.N., Parfrey P.S., Harnett J.D., Kent G.M., Murray D.C., Barre P.E. Hypoalbuminemia, cardiac morbidity and mortality in end-stage renal disease. J. Am. Soc. Nephrol. 1996; 7:728-736.
24. Danielski M., Ikizler A., McMonagle E., Conner Kane J., Pupim L., Morrow J. et al. Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodi-alysis therapy. Am. J. Kidney Dis. 2003; 42 (2): 286-294.
25. Don B.R., Kaysen G. Serum albumin: relationship to inflammation and nutrition. Semin. Dial. 2004; 17(6):432-437.
26. Yang W.S., Kim S.B., Min W.K., Park S., Lee M.S., Park J.S. Atherogenic lipid profile and lipoprotein(a) in relation to serum albumin in haemodialysis patients. Nephrol. Dial. Transplant. 1995; 10: 1668-1671.
27. Kim S.B., Yang W.S., Kang E.S., Min W.K., Park J.S. Lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease. Perit. Dial. Int.1997 ;17(3):236-242.
28. Kario K., Matsuo T., Kobayashi H., Matsuo M., Asada R., Koide M. High lipoprotein(a) levels in chronic hemodialysis patients are closely related to the acute phase reaction. Thromb. Haemostasis 1995; 74: 1020-1025.
29. Yun K.A., Lee W., Min W.K., Chun S., Lee Y.W., Kim S.B.et al. Discrepancy of interleukin-6 levels between end renal disease patients and patients with acute-phase response with increased lipoprotein(a)concentration. Scand. J. Clin. Lab. Invest. 2004; 64 (3): 223-228(6).
30. Wade D.P., Clarke J.G., Lindahl G.E., Liu A.C., Zysow B.R., Meer K. et al. Genetic influences on lipoprotein(a) concentration. Biochem. Soc. Trans. 1993; 21: 499-502.
31. Barter P., Gotto A.M., LaRosa J.C., Maroni J., Szarek M., Grundy S.M. et al. Treating to New Targets Investigators: HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med. 2007;357:1301-1310.
32. Dursunoglu D., Evrengul H., Polat B., Tanriverdi H., Cobankara V., Kaftan A. et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol. Int. 2005 ;25(4):241-245.
33. Panichi V., Migliori M., De Pietro S., Taccola D., Bianchi A.M., Giovannini L. et al. C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure. Nephron 2002;91:594-600.
34. Yang W.S., Kim S.B., Min W.K., Park J.S. Effect of increasing serum albumin on serum lipoprotein(a) concentration in patients on continuous ambulatory peritoneal dialysis. Am. J. Kidney Dis. 1997; 30:507-513.
35. Koda Y., Nishi Sh.I., Suzuki M., Hirasawa Y. Lipoprotein(a) is a predictor for cardiovascular mortality of hemodialysis patients. Kidney International 1999; 56: S251-S253.